Skip to main content
. 2016 Mar 18;7(17):23715–23729. doi: 10.18632/oncotarget.8173

Figure 2. Resistance profiles of ALK mutations against six ALK TKIs.

Figure 2

(A) Cell viability assays (with denoted IC50s) for each resistant line compared to the parental line from which they were derived. (B) Cellular transformation of FL5.12 cells infected with an MSCV-based vector co-expressing GFP and wild-type or mutant NPM-ALK constructs upon cytokine withdrawal. The kinase-dead mutant was unable to survive in the absence of cytokine (*). (C) IC50's for each FL5.12 NPM-ALK construct against six ALK TKIs (see also Supplementary Figure S2). (D) Same as (B) but with mutations created in a retroviral vector containing EML4-ALK. (E) IC50's for each FL5.12 EML4-ALK construct against six ALK TKIs (see also Supplementary Figure S4). Mean ± SEM for quadruplicates (A, C and E) or triplicates (B and D). (A, C and E) Unpaired two-tailed t-test was performed using GraphPad Prism version 6 to compare the IC50s for each mutant to their respective parental (A) or wild-type (C, E) cells. *p < 0.05, **p < 0.001.